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ABSTRACT 
 
This research analyzes the Food and Drug Administration’s (FDA) quality systems methodology 
through a detailed 12-year case study of McNeil Consumer Healthcare and its Ft. Washington, 
Pennsylvania manufacturing facility. This in-depth review, from 2000 to 2011, includes plant 
inspections reports, out-of-compliance findings, warning letters and a plant closure injunction. It 
then contrasts the specific findings of the McNeil case study with an analysis of overall FDA 
performance within the same sector of Finished Bio-Pharmaceuticals (BP). In addition, this case 
study pays particular attention to the role played by the FDA’s risk methodology in enhancing 
the overall inspection process and increasing its quality assurance. 
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FOOD AND DRUG ADMINISTRATION CASE STUDY 
 
The FDA is the supervisory agency that provides oversight and guidance to the bio- 
pharmaceutical (BP) industry. It safeguards the public by ensuring that BP products are safe, 
effective, and manufactured in accordance with current Good Manufacturing Practice (U. S. 
Food and Drug Administration, 2004a). This paper provides a case study of McNeil Consumer 
Healthcare and its main manufacturing facility at Ft. Washington, Pennsylvania, from 2000 to 
2011. Over this 12-year period, the case study details FDA activities at this site. This includes 
plant inspections, Form 483 observational reports (483), and warning letters (WLs), as well 
as recalls and plant closures. While it would be premature to extrapolate from one case study 
to overall FDA performance, it is fair to say that certain insights can be gained concerning 
procedures, performance, oversight, and governance. Similarly, these findings about FDA 
performance provide an opportunity to review how its newly adopted risk methodology and 
quality assurance practices are incorporated into its oversight practices. 
 
To put this case study into appropriate perspective, the findings were compared with other 
research that focuses on more quantitative studies of FDA performance using sector-wide data. 
The two principal academic investigations of FDA and quality assurance (QA) that we are aware 
of are Adis’ risk studies (2007; 2008), and Marcher and Nickerson’s (2006) review of quality 
systems. Both were sector evaluations, rather than a case study. 
 
The McNeil Ft. Washington facility is noteworthy in that it posed significant compliance 
challenges to the FDA during the 12-year period. There were several FDA Field Alerts about 
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failed manufacturing processes and several large scale recalls of such popular product as Motrin, 
Tylenol, and Listerine. 
 
The problems at this site have caused the FDA to take the unusual step of making available the 
Establishment Inspection Reports (EIRs) for this facility. With these reports, one can track FDA 
interactions with the Ft. Washington site and review FDA oversight and plant compliance 
(Betterchem, 2008). In other words, the researcher has an insider’s picture of quality assurance 
and risk prevention activities at Ft. Washington. 
 
The FDA rarely makes EIRs available because it respects manufacturers’ concerns about 
releasing proprietary and confidential information. In addition, part of its mandate is to provide 
guidance, so a non-adversarial environment is preferred. Therefore findings from EIR plant 
inspections are regularly withheld, even from the provisions of the Freedom of Information Act 
(U. S. Food and Drug Administration, 2008a). But in this instance, due to the seriousness of the 
infractions at the McNeil site, the FDA has released the 12-year history of inspections and 
oversight. Though this material has been heavily redacted to maintain confidentiality, it is still a 
valuable resource. Furthermore, due to the extent and flagrance of the violations, there are 
additional public documents: a consent Decree to close the Ft. Washington plant, transcripts of 
the FDA testimony at congressional hearings about McNeil’s recalls, and public statements from 
McNeil’s management and their parent company Johnson and Johnson. These were helpful in 
piecing together the activities of the principals, during this time period of 7 major recalls. 
 
The Center for Drug Evaluation Research (U. S. Food and Drug Administration, Center for Drug 
Evaluation and Research, 2007) is the FDA agency directly responsible for the Finished 
Pharmaceuticals sector that includes over-the-counter drugs. It has thousands of employees and 
performs hundreds of inspections per year. Consequently, this case study review can be only a 
very narrow investigation into its quality assurance activities. By reviewing the data in this 
case study, the research is establishing some anecdotal evidence about CDER performance and 
its use of quality assurance techniques. To broaden the findings, the research then looked at 
CDER’s activities and performance at inspection sites throughout the sector. 
 
 
BACKGROUND: MCNEIL CONSUMER HEALTHCARE, FT. WASHINGTON 
 
McNeil is a large sophisticated BP company that manufactures, packages, distributes and markets 
a range of pharmaceutical products including the over-the-counter drugs Tylenol and Motrin. Its 
annual sales in 2004 were US $2.1 billion. Its headquarters and major manufacturing facility 
employs 2,600 people and is located in Ft. Washington, Pennsylvania. The plant as a 
manufacturer of finished pharmaceuticals must meet the FDA current good manufacturing 
practices (cGMP). These guidelines are the basis for the quality assurance (QA) activities, and 
act as a barrier against manufacturing failures (U. S. Food and Drug Administration, Center for 
Drug Evaluation and Research, 2009). 
 
Yet, throughout this case study time period, QA problems at Ft. Washington caused McNeil to 
notify the FDA on the necessity of issuing Field Alerts and Recalls. For instance, in the 
2008-2010 period, there were two major recalls from the Ft. Washington plant involved the 
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production of Motrin and Children’s Tylenol, resulting in more than 100 million bottles being  
pulled from the distribution channel (U. S. Food and Drug Administration, 2011b). Many 
consider this one of the largest recalls of child medication in FDA history. 
 
This triggered an FDA site inspection which found significant quality-control problems and 
detected metallic particles in the children’s medications. Based on this inspection, McNeil 
recalled an additional 136 million bottles of pediatric medications, and ceased production. 
 
During this same period, McNeil faced additional recalls of certain medications. These included 
Benadryl, Motrin, adult Tylenol and Zyrtec products from the Ft. Washington site. The cause for 
these multiple recalls was the chemical breakdown of a protective coating on wooden transport 
pallets causing a moldy odor. This was absorbed by the pharmaceuticals products. 
 
It should be noted that a recall by definition is a flagrant QA violation in which there is a 
reasonable probability that the use of or exposure to a violative product will cause serious 
adverse health consequences or death. The majority of McNeil’s recalls are Class I, the most 
serious category. 
 
One of the more telling events occurring at the end of the study period was the McNeil Consent 
Decree of Permanent Injunction (United States v. McNeil, 2011). The basis of the Decree was 
that McNeil and certain corporate officers had allegedly manufactured, processed, packed, 
labeled, held, and distributed drugs that were in violation of cGMP. The Decree names the 
McNeil Corp of New Jersey, which does business in Pennsylvania and elsewhere, and key 
defendants such as the VP of Quality Control and the VP of Operations. The Decree 
permanently restrained and enjoined McNeil to stop activities at Ft. Washington until cGMP 
were certified as restored. McNeil consented to this without admitting or denying the allegations, 
yet immediately shuttered the Ft. Washington facility. 
 
The United States Congress did not regard these recalls as trivial events, and began their own 
investigation into the FDA—McNeil situation. Without a doubt, the scale of the recalls and the 
popularity of the drugs involved, caused Congress to want to know more about McNeil’s quality 
controls, as well as the FDA’s supervisory oversight (Sharfstein, 2010). This investigation most 
likely was instrumental in having the FDA release the previously classified Ft. Washington site 
inspections reports. The release of these documents allowed the congressional committee, as well 
as researchers, to probe quality assurance activities at both t h e  FDA and McNeil for the 
last 12 years. 
 
 
FDA’S cGMP 
 
The FDA functions as the responsible supervisory agency to the BP industry, mandating quality 
systems (GAMP, 2003) in all aspects of the manufacturing life cycle of drugs, vaccines, and 
other biological products. Its oversight tasks are to inspect facilities to ensure that industrial 
standards for purity, potency, and quality for drug manufacturing are maintained. The agency 
examines biological products and manufacturing processes, issues warning letters, and takes 
enforcement action, such as ordering recalls. The regulatory guidelines (U. S. Food and Drug 
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Administration, 2003a & 2004a) have an exceptionally low tolerance for variability or 
nonconformity in all pharmaceutical products and processes. 
 
These oversight tasks continue to grow as the number of BP research and production sites 
become more numerous. Yet the Agency’s resources have not expanded proportionally, 
consequently its resources are constrained. It has a limited budget, and is understaffed, and 
possibly not fully trained to meet the new technologies in the BP industry. These inadequacies 
prevent it from meeting its goals of inspecting domestic BP facilities on a regular basis. More 
specifically, it cannot meet its mandated 2 year inspection cycle, or its 4 year cycle for more 
complex products and processes. This dearth of resources if not addressed, will create either an 
increasing backlog of site inspections on one hand, or on the other hand, more partial inspections. 
 
To meet this supervisory bottleneck, the FDA chose to supplement its industrial best practices 
inspections with a quality assurance methodology that orders and prioritizes BP sites based on 
their associated risk (U. S. Food and Drug Administration, 2004b). This transition began in 2004, 
when the agency adopted this new risk-based methodology, outlined in part by the 
Pharmaceutical Current Good Manufacturing Practices (cGMP) for the 21st Century (U. S. Food 
and Drug Administration, 2004a). 
 
This methodology streamlines the oversight process, choosing manufacturing facilities with the 
highest risk priority, pinpointing the focus for the site inspection, and determining whether 
warning letters and recalls are necessary (U. S. Food and Drug Administration, 2008b). “The 
model is based on a risk-ranking and filtering method that is well-recognized, objective, and 
rigorously systematic. The Agency believes that this methodology makes the best use of its 
limited surveillance and enforcement resources, while maximizing the impact of those resources 
on the public health” (U. S. Food and Drug Administration, 2004a). 
 
More specifically, this research analyzes the role of quality assurance as detailed in the cGMP 
regulations. Prominent within these are the concepts of corrective and preventative action 
(CAPA) for risk management. CAPA is a critical component for sustainable compliance since 
problem prevention, containment, and remediation are intrinsic in determining the outcome 
(COSO, 2004). In this new rubric, site inspectors use the CAPA component to help monitor 
system performance, record keeping, staffing qualifications, and quality assurance (ICH, 2005; 
U. S. Food and Drug Administration, 2003b & 2006). 
 
As part of this ongoing CAPA process, the FDA increments their normal inspection schedule 
with priority inspections for those manufacturing sites that have a previous history of 
nonconforming production practices, or perform processes that have an inherently higher risk of 
system failure (U. S. Food and Drug Administration, 2008c). In this way, the FDA builds a 
performance history for each manufacturer, focusing on these risk management statistics (ICH, 
2007): 
 
• Overall compliance status and history of the company and facility 
• Results of the company’s quality risk management activities 
• Complexity of the manufacturing process 
• Complexity of the product and its therapeutic significance 
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• Number and significance of quality defects (e.g., recalls) 
• Results of previous audits/inspections 
 
One of the research tasks is to analyze McNeil inspection documents to judge the effectiveness 
of the CAPA risk management methodology during the 12-year period. 
 
 
RESEARCH METHODOLOGY 
 
The researchers examined the FDA reports about the McNeil Ft. Washington facility, and paid 
particular attention to those issues that dealt with cGMP, quality assurance and CAPA. As 
mentioned in the previous section, the research looked into FDA performance, judged by 
frequency and depth of the inspections, violations cited, and the guidance given by the FDA. 
This was then contrasted against the actual field alerts, recalls and plant closing. The basic 
question for the research is - Did the FDA provide sufficient CAPA oversight? The corollary 
being - With more oversight could these events be eliminated? 
 
Using published documents and the Freedom of Information Act, the research was able to review 
FDA activity that met the following criteria: 
 
• Took place at the McNeil Ft. Washington facility during 2000-2011 time period. 
• Subject was cGMP found in regulations 501(h) of the Act (21 U.S.C. §351(h)) (U. S. 
Food and Drug Administration, 2008c) 
• Specifically addressed cGMP Practice for Finished Pharmaceuticals 
• QA and CAPA risk methodology as mentioned directly or indirectly in FDA regulation 
Part 211. 
 
Within this framework, the researchers reviewed in detail the supervisory activities of the FDA 
relating to the Ft. Washington facility. These activities are listed in in Table 1, with the first 
column being the common name used by the FDA, followed by a brief definition (U. S. Food 
and Drug Administration, 2008c). For the most part they are self-explanatory, though the more 
important ones, such as warning letters (WLs), will be further developed as the paper 
proceeds. It should be noted that for the most part, the referenced activities in the table are in 
logical order of growing importance. Category 1 contains CAPA activities to correct and prevent 
production problems. For instance, the EIR report documents the inspection. This is followed by 
an observation Form 483, listing objectionable conditions found during the inspection. The last 
entry in this category is the Warning Letters (WLs) for violations of regulatory significance, and 
establishing prior notice before judicial action. 
 
This grouping is followed in the table by Category 2, another class of CAPA activities that 
focusses on alerting the distribution chain about problems of non-conforming batches of drugs. 
This is done when the manufacturer, in collaboration with the FDA, issue field alerts (U. S. 
Food and Drug Administration, 2011a), and if necessary recalls products. 
 
Category 3 addresses the most serious FDA enforcement activities: consent decrees to halt 
manufacturing and full plant closure. When the FDA realize that their CAPA activities have 
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failed to eliminate hazards, they turn to the courts for legal action such as requesting an 
injunction to temporarily stop production, or to close manufacturing operations. These  
enforcement actions are sometimes bypassed when the manufacturer voluntarily closes the plant 
to attempt to avoid the negative publicity of an FDA closure. 
 
Category 1 FDA Corrective and Preventive Activities 
EIRs Establishment Inspection Report: The EIR documents the inspection. FDA guidelines establish a 
2-4 year manufacturing inspection cycle, plus additional inspections based on risk evaluation. 
483s FDA Form 483: A summary of objectionable conditions listed in the EIR or related documents 
which are cited to support specific regulatory recommendations. These become the basis for WLs. 
WLs Warning Letters are issued only for violations of regulatory significance. Significant violations are 
those that may lead to enforcement action if not promptly and adequately corrected. WLs are the 
agency's principal means of achieving prompt voluntary compliance and establishing prior legal 
notice. 
Category 2 FDA and Manufacturer CAPA Remediation Activities 
Field Alerts A manufacturer is required to file a Field Alert when an anomaly occurs in the manufacturing, viz., 
testing, processing, packing, labeling, storage, or distribution of a licensed biological. In particular 
those anomalies in which the safety, purity, or potency of a distributed product may negatively 
impact the public health. Certain Field Alerts may escalate to recalls of distributed products. 
Recalls Recalls are actions taken by a firm to remove a product from the market. Recalls may be conducted 
on a firm's own initiative, by FDA request, or by FDA order under statutory authority. A recall 
means there is a reasonable probability that the use of or exposure to a violative product will cause 
serious adverse health consequences. 
Category 3 FDA Enforcement 
Consent Decree Consent Decree of Permanent Injunction. An agreement by a defendant to an action to 
discontinue all activities viewed by the government as being illegal. 
This agreement occurs with the consent of both parties to the action and has court approval but 
stops short of a definitive judicial determination. 
Plant Closing An example is the voluntary plant closing by McNeil and Johnson and Johnson’s management, 
prior to the issuance of the Consent Decree. 
Category 4 Congressional Investigative Activities 
Congressional 
Investigation 
Congressional Committee on Oversight and Government Reform hearing on FDA oversight of 
McNeil. 
 
Table 1: Review of Major FDA Topics. 
 
The final category is congressional investigative activities. These investigations are only initiated 
where the number and type of recalls are significant. In this instance, Congress chose to review 
the FDA-McNeil business interactions. 
 
Of all the items listed in Table 1, the researchers were particularly interested in how the CDER 
uses Warning Letters (WLs), since it is one of the stronger enforcement mechanisms. By 
formally establishing prior notice, the WL has the ability to both warn and guide manufacturers 
to correct significant regulatory violations. As the FDA states , “(A) Warning Letter is the 
agency's principal means of achieving prompt voluntary compliance with the Federal Food, 
Drug, and Cosmetic Act (the Act).” (U. S. Food and Drug Administration, 2012) 
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Furthermore, much can be learned by the CDER criteria for issuing WLs: 
 
1. The violation reflects a history of repeated or continual conduct during which time the firm 
has been notified of a similar violation 
2. There is a violation of cGMP in terms of manufacturing, ingredients, dosage, quality systems 
and oversight 
3. The product contains illegal pesticide residues 
4. The product shows short contents, subpotency, or superpotency 
 
It is easy to see why WLs are a critical enforcement tool for the FDA in dealing with 
manufacturing QA failures. The WLs, together with the other McNeil related documents, present 
a dynamic picture of interactions between the FDA and the McNeil during this 12 year period. 
 
 
ANALYSIS 
 
In 2010 McNeil voluntarily closed the Ft. Washington plant. This closing took place while a 
court ordered injunction to cease manufacturing was in its initial phases of the proceedings. In 
the following year a congressional investigation began into the interactions between the FDA 
and McNeil. Its initial focus was on their latest recalls, but expanded into other areas over time. 
 
In a similar way, this research seeks to understand the level of oversight and guidance shown by 
the FDA to McNeil in this time period. 
 
To address these issues, the researchers summarized the FDA-Ft. Washington interactions 
between 2000-2011 (see Table 2). The data in the table ranges from EIR Inspections to Recalls, 
and from Consent Degree to Congressional Investigation. In this way the data represents a time 
chart showing the correspondence between CDER activity and QA problems at the Ft. 
Washington plant. 
 
Table 2 shows that CDER addressed the Ft. Washington QA issues with 13 inspections, rather 
than the 3 or 4 that is typical for a well-functioning plant over a similar time period. The 
inspections were detailed enough to generate seven 483 Reports for objectionable conditions. 
The inspectors determined in many instances the root causes of these problems stemmed from 
the cGMP areas of QA and CAPA. So in one sense, the CDER did its job with guidance and ever 
stricter oversight. Furthermore, in reading those EIR reports, particularly in the years 2000-2007, 
one can loosely conclude that McNeil remedied those reported quality control conditions, 
improved their best practices and minimized or eliminated any previously stated objectionable 
conditions. This was demonstrated by several years with either no inspections, or inspections 
with no 483 reports of objectionable conditions. 
 
However, this preliminary interpretation may be incorrect in light of the serious QA problems 
that occurred later in 2008-2011. Researchers know that QA and risk avoidance methodologies 
are built on sustainable manufacturing practices, or what Booch (1994) calls “industrial strength” 
systems. The fundamental feature of an industrial strength system is day-in day-out quality and 
reliability throughout the life cycle of production. Manufacturing quality problems do not 
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suddenly materialize but are the result of failures over time. So it is a concern that the 483s, field 
alerts, and recalls of the earlier time period 2000-2002 are in fact repeated in the later 2008-2010 
period. 
 
 Years 
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 Total 
Category 1 CAPA Activities              
EIRs 1  1 2 2  2  1 2 3  13 
483s 1    1  1  1 1 2  7 
WLs             0 
Category 2 CAPA Remediation              
Field Alerts 2            2 
Recalls  1 1      1 2 2  7 
Category 3 Enforcement              
Consent Decree            1 Mar. 1 
Plant Closing           1 Apr.  1 
Category4 Investigative              
Congress Investigation           1  1 
Totals 4 1 2 2 3 0 3 0 3 5 9 1  
 
Table 2: Summary of CDER McNeil Activity. 
 
With this in mind, the researchers reviewed the same data on a more granular level by looking at 
three periods: the early years (2000-2002), the mid years (2003-2007) and the later years (2008-
2010). This breakdown into 3 groups reflects CDER McNeil interactions shown in Table 2. 
There was much CDER activity in the beginning period based on QA problems serious enough 
to warrant field alerts and recalls. Similarly during the end period of the study (2008-2010) there 
were also serious systemic problems that culminated in a FDA initiated court injunction to close 
the plant. In the middle years, there were significantly less problems noted, with no field alerts or 
recalls. It is the 5 year middle period that is of particular concern. 
 
It raises these question: 
 
• If QA and CAPA were adequately addressed in the initial years, why did they return later? 
• Was there weakness in the FDA oversight mechanism? 
• Did the manufacturer’s solutions actually meet the FDA cGMP standard? 
 
In sum, the researchers wanted to know in greater detail if the FDA oversight was proportional to 
McNeil’s QA and CAPA failures. 
 
The study period begins in 2000 with an EIR inspection, leading to a 483 report, and 2 field 
alerts. Then in 2001, the field alert expands into a recall. Yet there are no inspections in 2001 to 
investigate this situation. Actually for most of the study period (2000-2007), when CDER 
carried out inspections and found objectionable conditions, it gave the site 2 years to remedy the 
problem before it recommenced inspections. Furthermore, CDER often issued 483s in an ‘on 
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again off again’ fashion. There were 5 years where there were no 483s interspersed with 6 years 
when inspections yielded 483s .The underlined years show the absence of 483s (2000, 2001, 
2002, 2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010). 
 
This runs counter to CDER best practices and cGMP methodology which specifically calls for 
increased focused activity based on the risk detailed in EIRs and 483s. 
 
Then even more strikingly, at no time during this 11 year period that culminated in an injunction 
order to cease manufacturing and a plant closing, did CDER issue a warning letter. As discussed 
earlier, a WL is one of the FDA’s principal enforcement tools used to establish prior notice 
before stringent enforcement or penalties are invoked. Without due diligence on the part of the 
FDA and McNeil, the manufacturing problems would tend to persist, and therefore the risks to 
the public would remain. By contrast, CDER in the last 3 years of this period (2008-2011) was 
proactive, following their own methodology, and did in fact exercise due diligence. Yet CDER 
still did not issue any warning letters. 
 
Without WLs to review, the research then turned to 483 reports of objectionable QA conditions, 
particularly those between 2004-2011. As was mentioned earlier, in 2004 the FDA 
established the new cGMP standards emphasizing quality and CAPA activities. Therefore from 
2004, the 483s would uniformly reference the same cGMP standards, and this would clarify the 
degree to which CDER exercised the necessary oversight. Table 3 addresses this by showing the 
persistent QA problems between 2004 and 2011. 
 
Table 3 presents the contents from three reports: 483s for June 2004 and April 2010, and the 
Consent Decree of 2011. The contents of these documents have been summarized and the 
language modified for the sake of clarity. The table uses standard CDER categories: quality 
systems, packaging, laboratory, and facility and equipment systems. The recurrent theme in all 
three documents is that McNeil had substandard QA throughout its operations. 
 
CDER determined that one of the main reasons for this inadequacy was that the quality 
control unit was not integrated with plant operations, and consequently failed to supervise, audit, 
and provide the necessary support. For instance, in the Quality Systems category there was 
failure to thoroughly review any unexplained discrepancy. Specifically, investigations did not 
always include appropriate QA documentation, nor were they timely or complete. That 
general lack of QA integration was repeated throughout the report, regardless of category. 
 
Does this mean that after the detailed 2004 findings there was a dramatic improvement at Ft. 
Washington, then in the later period, an equally dramatic reversion to previous inferior 
standards? Or were CDER efforts at coaxing and providing ‘soft’ guidance, in fact unsuccessful? 
Or in fact, did certain interim inspections tend to be pro forma and lackadaisical as indicated by 
the brief 483 report of 2006 with only three observations? 
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Major Quality Assurance Functional Areas 
483 
June 
2004 
483 
April 
2010 
Decree 
March 
2011 
Quality Systems 
   
a. Failure to thoroughly review any unexplained discrepancy. Specifically, 
investigations did not always include appropriate QA documentation, nor were 
they always timely or complete. 
   
b. Unexplained discrepancy did not extend to other drug products that may have 
been associated with the specific failure or discrepancy.    
c. Responsibilities and procedures applicable to the quality control unit are not in 
writing and fully followed.    
d. No written procedures for review of complaints, returned drug products, and 
conducting investigations.    
Packaging System    
e. Strict control is not exercised over labeling drugs products.    
f. Labeling and packaging materials are not representatively sampled and examined.    
g. Quality Control unit did not review and approve procedures for packaging and 
reprocessing.    
Laboratory    
h. Batch production and control records do not include all necessary information.    
i. Laboratory records do not include necessary information: description of the 
sample received for testing, its source or location, the quantity and date of the 
sample. 
   
j. Quality control unit does not review or approve changes to equipment 
specifications or procedure.    
Facilities and Equipment System    
k. Written procedures are not established and followed for the cleaning and 
maintenance of equipment used in the manufacture, processing, packing or 
holding of drugs. 
   
l. Representative samples are not taken of each lot shipment for testing or 
examination.    
 
Table 3: QA Problems Between 2004 and 2011. 
 
These somewhat rhetorical questions cannot be answered through one case study, particularly 
since the EIRs and the 483s were filled with much redacted material. Yet the idea that the site 
performed poorly at the beginning of the period, followed by dramatic improvements and then 
reversals, does not concur with known data on building sustainable QA (de Neufville, 2004). 
More information and insight are needed, and the 2011 Consent Decree to cease manufacturing 
provides some of that. 
 
The Consent Decree addresses the same issues as in the 483s. In addition, it mandates that 
McNeil has the legal obligation to 
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• Hire a cGMP expert to ensure that the Ft. Washington manufacturing facility corrects 
deficiencies in methods, facilities, processes, and controls used to manufacture, process, pack, 
hold, and distribute drugs 
• Develop a comprehensive, written quality assurance and quality control program that is 
adequate to ensure continuous compliance. This entails coordination with and appropriate 
oversight by the parent company, Johnson & Johnson 
• Ensure the continuous compliance with the cGMP federal regulations relating to the safety, 
identity, strength, quality, and purity of drugs 
• Have a Quality Control Unit, that is adequately qualified, trained and staffed to evaluate 
cGMP compliance on an ongoing basis to prevent and promptly correct future 
deviations 
 
Faced with a recalcitrant McNeil, who were unable or unwilling to make the effort to achieve 
continuous compliance, CDER was fully challenged over the 12 year period. Like McNeil, 
CDER gives the impression that it was unable or unwilling to increase its oversight in terms of 
inspections, 483s, or WLs. Since CDER did not issue one WL to Ft. Washington over that time 
period, it would be hard to conclude that CDERs level of oversight was appropriate to the QA 
failures and dangers posed by Ft. Washington. Only in the last few years did CDER enforcement 
match the obdurance of McNeil. 
 
Even the introduction of the new risk based cGMP in 2004 did not improve the overall safety of 
the plant, or strengthen the QA functions. 
 
 
DISCUSSION 
 
This research case study focused on one manufacturing facility within the BP sector. This 
targeted analysis spotlighted CDER activity over a 12 year period. Yet there are thousands of 
plants that produce finished pharmaceuticals. Therefore the findings by their very nature are 
limited, though arguably important for the following reasons: 
 
• This is one of the few times the FDA has published EIRs and 483s showing their activity 
• The McNeil facility produces popular non-prescription drugs: Motrin and Tylenol 
• The plant has had recalls of millions of units over a 12 year period 
• Johnson and Johnson, the parent company, has a well-established reputation for quality  
 
While it is impossible to extrapolate from one case study, it is fair to ponder how CDER could 
fail to follow its own cGMP guidelines in facing this persistent series of QA failures. The same 
type of question may be asked about McNeil, one of the leading pharmaceutical manufacturers. 
There is no clearer indication of CDER procedural shortcomings than its failure to issue any 
WLs, the preliminary step for future enforcement activities (Goldstein, 2008). The researchers 
wanted to determine whether this lack of WLs was unique to the CDER-Ft. Washington 
interaction or was part of a larger trend in the BP sector for finished pharmaceuticals. To do this, 
the researchers reviewed WLs that meet the QA criterion of cGMP Part 211 based site 
inspections during the period 2003-2011. 
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This data was derived from the FDA document 2010 FDA’s Field Activities—Office of 
Regulatory Affairs (United States Food and Drug Administration, Center for Drug Evaluation 
and Research, 2011) and other congressional reports (Crosse, 2008). These reports to Congress 
contain very useful data including budgetary and staffing information and field activities. Using 
these resources, it was straightforward to determine the total number of field inspections per 
year, as well as those that triggered WLs. 
 
Table 4 shows CDER activity at facilities that manufacture finished pharmaceuticals. It displays 
the total number of inspections per year and WLs that were issued based on violations at those 
sites. During the time period 2003 to 2011, the number of inspections ranged from 983 and 
1365, while the WLs from 13 to 48. Neither the number of WLs nor their percentages (Column 
C) seem particularly significant, given the large number of inspections. There does not seem to 
be any particular impact from the introduction of cGMP risk methodology in 2004. The WLs 
vary between 1% and 4% of the yearly inspections regardless of methodology. This modest 
number is in keeping with what we know regarding the FDAs problems of limited staff, budget, 
and resources that prevent the agency from expanding the number of inspection of manufacturing 
sites, regardless of methodology. 
 
Year 
(A)Total 
Inspections 
(B)Part 
211WLs 
(C)Percent(B
/A) 
2003 1,149 35 3.0% 
2004 1,232 26 2.1% 
2005 1,365 14 1.0% 
2006 1,222 20 1.6% 
2007 1,073 13 1.2% 
2008 972 29 3.0% 
2009 983 26 2.6% 
2010 1,174 48 4.0% 
2011 983 * 38 4.2%* 
* FDA estimate 
 
 
Table 4: FDA Inspections (Part 211) and Corresponding WLs 
for the Finished Pharmaceutical Sector. 
 
Facing the paucity of WLs throughout the sector, it is hard to argue that CDER is concentrating 
on the most risk prone manufacturers. Ft. Washington certainly is a good example of the latter. 
If CDER’s objective is to use cGMP methodology to focus its limited resources on risk prone 
manufacturers, then there is seemingly a significant gap between the theory and practice. McNeil 
is a real world example of missing inspections, 483s, and WLs in spite of the objectionable 
conditions, field alerts and recalls. 
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Perhaps the focus should be moved from the cGMP risk methodology, to its implementation by 
CDER. One may plausibly argue that Ft Washington is in miniature a representation of CDER 
overall performance, with few inspections, and even fewer sites with WLs. In fact CDER may 
be so constrained that cGMP cannot be fully implemented. 
 
Before more definitive statements can be made, supplemental topics need exploration. A broader 
research agenda may point to a different understanding of the FDA inspection process. For 
instance, additional information would include aggregation of the following BP sector 
information: 
 
• CDERs actual enforcement policy 
• The amount of experience and training inspectors have with CAPA and risk methodologies 
• Specific data about product recalls, fines and penalties imposed by CDER 
• Manufacturers’ litigation history against the FDA 
 
The researchers intend also to continue building other case studies to see if they in fact replicate 
the patterns shown in the Ft. Washington. With this type of research using case studies and 
broad sector analysis, the researchers are continuing to probe how CDER is meeting its workload, 
in spite of limited staff and resources, and its mandatory oversight within a technically and 
politically complex environment. 
 
 
CONCLUSION 
 
The current history of CDER-McNeil Ft. Washington in one sense confirms the budgetary and 
resource problems faced by the FDA. The McNeil case study puts a face on the decreasing 
CDER momentum, in terms of cGMP inspections and WLs. It also puts a face on the 
consequences to the public. Yet when the FDA does focus on a problem facility, as occurred in 
the last few years at Ft. Washington, its enforcement actions were clear and strong, forcing the 
plant to cease manufacturing. So we have a dual picture, one of CDER weighed by its 
constraints, the other sharply in focus when events get out of hand. 
 
In summary, the inconclusive CDER activities at Ft. Washington (2000-2007): 
 
• Inconsistent EIR inspections, in spite of field alerts and recalls 
• Correspondingly, few 483 reports in spite of failure to remedy conditions 
• Failure to issue cGMP WLs when facing persistent and significant QA problems 
 
The more focused CDER enforcement (2008-2011): 
 
• Frequent and rigorous inspections 
• Detailed 483s documenting objectionable conditions 
• Recalls on products 
• Judicial Action through Consent Decree 
• Forced plant closure 
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If the FDA is using the inspection process as a policy tool for guiding ‘willing’ manufacturers to 
more sustained compliance, then in this instance it has failed. Likewise, it should be noted in 
this case study that the more serious step of issuing 483s of objectionable conditions did not by 
itself trigger McNeil to remediate the CAPA problems. 
 
This case study points to the fact that inspections and 483s are a ‘necessary but not sufficient’ 
activity by CDER. When faced with manufacturer’s recalcitrant behavior, WLs become an 
essential enforcement step. As a public document, the WL alerts the manufacturer and the 
consumer to flagrant quality control failures, and the possibility of legal action. With certain 
uncooperative manufacturers, this step has to become mandatory. When CDER fails to issue 
WLs necessary to protect the public safety, this conduct borders somewhere in the territory 
between negligence and incompetence. 
 
The escalation of enforcement is clearly part of CGMP and CAPA methodologies, and therefore 
the issue in this case study is failure to implement procedures. The researchers in future studies 
would be interested in exploring the source of the failures. In addition to the budgetary and 
resource constraints mentioned earlier, other issues could be: 
 
• Was CDER reluctant to go up against a Johnson and Johnson subsidiary, with its 
sophisticated legal staff? 
• How many of McNeil current staff are former CDER employees? If the BP sector is a 
likely future employer for CDER staff, are there steps to safeguard the inspection process 
from favoritism? 
 
Through additional case studies, the researchers plan to look deeper into those quality issues that 
have dogged McNeil, and should have been addressed more seriously by CDER. 
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